BioNano Genomics Inc (NASDAQ:BNGO) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 12,700 shares, an increase of 154.0% from the July 31st total of 5,000 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 17,000 shares, the short-interest ratio is presently 0.7 days.

Several brokerages have recently issued reports on BNGO. ValuEngine upgraded shares of BioNano Genomics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research report on Monday, August 26th. Finally, Maxim Group restated a “buy” rating and set a $7.00 price target on shares of BioNano Genomics in a research report on Friday, August 9th.

Shares of BioNano Genomics stock traded up $0.11 during mid-day trading on Wednesday, reaching $1.18. 107,453 shares of the stock traded hands, compared to its average volume of 39,440. The business has a 50-day moving average of $1.86 and a 200 day moving average of $3.12. BioNano Genomics has a fifty-two week low of $1.01 and a fifty-two week high of $10.00. The stock has a market capitalization of $11.54 million and a PE ratio of -0.45. The company has a quick ratio of 2.77, a current ratio of 3.17 and a debt-to-equity ratio of 3.13.

BioNano Genomics (NASDAQ:BNGO) last released its earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.14). The firm had revenue of $2.18 million during the quarter, compared to analysts’ expectations of $2.56 million. BioNano Genomics had a negative net margin of 247.03% and a negative return on equity of 347.02%. On average, equities research analysts expect that BioNano Genomics will post -2.55 EPS for the current fiscal year.

BioNano Genomics Company Profile

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

See Also: What are gap-up stocks?

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with's FREE daily email newsletter.